Opexa (NASDAQ: OPXA) is a biopharmaceutical company developing a personalized immunotherapy with the potential to treat major illnesses, including multiple sclerosis (MS) as well as other autoimmune diseases such as neuromyelitis optica (NMO), according to the company’s website (see here: www.OpexaTherapeutics.com). SNNLive spoke with Neil K. Warma, President & CEO of Opexa Therapeutics, Inc. at the Marcum MicroCap Conference 2015 in New York City, NY.
Mr. Warma begins with a brief overview of the Company, “We’re focused on the treatment of autoimmune diseases. So, we’ve got a novel T-cell immunotherapy; personalized medicine for the treatment of autoimmune disease. We’ve been focused for the better part of a decade on the treatment of multiple sclerosis. We’re now in a late stage clinical trial in progressive MS, and we’ve recently launched an orphan indication, as well, off of our T-cell platform.” He continues with a discussion about the size of the multiple sclerosis market.
Mr. Warma goes on to explain his motivation for joining the Company, the science and history behind Opexa’s T-cell platform, and what ‘fast track designation’ means and how that affects the Company. Since speaking with Mr. Warma, the company has made the following announcements:
For more information about Opexa Therapeutics, Inc., go to: www.OpexaTherapeutics.com
© 2017 Stock News Now
Supported by Superior Web Solutions